Publications by authors named "Steven A Feldman"

Claim this Profile
E
Enabling access to genetically modified cell therapies through flexible approaches to manufacturing and cost recovery.
Mark D Stewart, Christopher R Cabanski, Jeff D Allen, John E Connolly, Ben M Beneski, Steven A Feldman

J Immunother Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and Cytokine Features of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome.
Hrishikesh K Srinagesh, Anne Marijn Kramer, John H Baird, Agnes Reschke, Bita Sahaf, Steven A Feldman

Blood Cancer Discov· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Automated manufacturing of cell therapies.
Alice Melocchi, Brigitte Schmittlein, Sudeshna Sadhu, Sunaina Nayak, Angela Lares, Steven A Feldman

J Control Release· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL.
Yi-Jiun Su, Anne Marijn Kramer, Mark P Hamilton, Neha Agarwal, Hrishikesh K Srinagesh, Steven A Feldman

Cancer Discov· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intravenous and intracranial GD2-CAR T cells for H3K27M diffuse midline gliomas.
Michelle Monje, Jasia Mahdi, Robbie Majzner, Kristen W Yeom, Liora M Schultz, Steven A Feldman

Nature· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Intravenous and intracranial GD2-CAR T cells for H3K27M diffuse midline gliomas.
Michelle Monje, Jasia Mahdi, Robbie Majzner, Kristen W Yeom, Liora M Schultz, Steven A Feldman

Nature· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency.
Justin A Guerrero, Dorota D Klysz, Yiyun Chen, Meena Malipatlolla, Jameel Lone, Steven A Feldman

Nat Commun· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.
Matthew J Frank, John H Baird, Anne Marijn Kramer, Hrishikesh K Srinagesh, Shabnum Patel, Steven A Feldman

Lancet· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential intravenous and intracerebroventricular GD2-CAR T-cell therapy for H3K27M-mutated diffuse midline gliomas.
Michelle Monje, Jasia Mahdi, Robbie Majzner, Kristen Yeom, Liora M Schultz, Steven A Feldman

medRxiv· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.
Liora M Schultz, Nikeshan Jeyakumar, Anne Marijn Kramer, Bita Sahaf, Hrishi Srinagesh, Steven A Feldman

Leukemia· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inosine induces stemness features in CAR-T cells and enhances potency.
Dorota D Klysz, Carley Fowler, Meena Malipatlolla, Lucille Stuani, Katherine A Freitas, Steven A Feldman

Cancer Cell· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoantigen-directed therapeutics in the clinic: where are we?
Lien Lybaert, Kris Thielemans, Steven A Feldman, Sjoerd H van der Burg, Cedric Bogaert

Trends Cancer· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing.
Hyatt Balke-Want, Vimal Keerthi, Nikolaos Gkitsas, Andrew G Mancini, Gavin L Kurgan, Steven A Feldman

Mol Cancer· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inosine Induces Stemness Features in CAR T cells and Enhances Potency.
Dorota D Klysz, Carley Fowler, Meena Malipatlolla, Lucille Stuani, Katherine A Freitas, Steven A Feldman

bioRxiv· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges in neoantigen-directed therapeutics.
Lien Lybaert, Steve Lefever, Bruno Fant, Evelien Smits, Bruno De Geest, Steven A Feldman

Cancer Cell· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-infusion CAR T cells identify patients resistant to CD19-CAR therapy.
Zinaida Good, Jay Y Spiegel, Bita Sahaf, Meena B Malipatlolla, Zach J Ehlinger, Steven A Feldman

Nat Med· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes.
Nikolaos Zacharakis, Lutfi M Huq, Samantha J Seitter, Sanghyun P Kim, Jared J Gartner, Steven A Feldman

J Clin Oncol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.
Robbie G Majzner, Sneha Ramakrishna, Kristen W Yeom, Shabnum Patel, Harshini Chinnasamy, Steven A Feldman

Nature· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Scalable Manufacturing of CAR T cells for Cancer Immunotherapy.
Mohamed Abou-El-Enein, Magdi Elsallab, Steven A Feldman, Andrew D Fesnak, Helen E Heslop

Blood Cancer Discov· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma.
John H Baird, Matthew J Frank, Juliana Craig, Shabnum Patel, Jay Y Spiegel, Steven A Feldman

Blood· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery.
Shin-Heng Chiou, Diane Tseng, Alexandre Reuben, Vamsee Mallajosyula, Irene S Molina, Steven A Feldman

Immunity· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma.
Stephanie L Goff, Richard A Morgan, James C Yang, Richard M Sherry, Paul F Robbins, Steven A Feldman

J Immunother· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience.
Kenneth Cornetta, Lisa Duffy, Steven A Feldman, Crystal L Mackall, Marco L Davila

Mol Ther Methods Clin Dev· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer.
Nikolaos Zacharakis, Harshini Chinnasamy, Mary Black, Hui Xu, Yong-Chen Lu, Steven A Feldman

Nat Med· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis